BIOMÉRIEUX |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 93.8 EUR | -0.90% |
|
-3.45% | -6.76% |
| May. 29 | BioMérieux: head injury test cleared by the FDA | CF |
| May. 28 | BioMérieux: FDA clearance for Vidas TBI test | CF |
| Sales 2024 * | 3.9B 4.2B | Sales 2025 * | 4.19B 4.51B | Capitalization | 11.08B 11.93B |
|---|---|---|---|---|---|
| Net income 2024 * | 468M 504M | Net income 2025 * | 529M 570M | EV / Sales 2024 * | 2.79 x |
| Net cash position 2024 * | 217M 234M | Net cash position 2025 * | 400M 431M | EV / Sales 2025 * | 2.55 x |
| P/E ratio 2024 * |
24.3
x | P/E ratio 2025 * |
21.4
x | Employees | 13,696 |
| Yield 2024 * |
0.95% | Yield 2025 * |
1.11% | Free-Float | 36.23% |
More Fundamentals
* Assessed data
More news
Latest transcript on bioMérieux
More recommendations
More press releases
More news
| 1 day | -0.90% | ||
| 1 week | -3.45% | ||
| Current month | -3.45% | ||
| 1 month | -5.35% | ||
| 3 months | -5.60% | ||
| 6 months | -4.17% | ||
| Current year | -6.76% |
1 week
93.75
97.55
1 month
91.80100.90
Current year
91.80108.90
1 year
84.54108.90
3 years
77.48133.20
5 years
67.45144.80
10 years
25.44144.80
| Managers | Title | Age | Since |
|---|---|---|---|
Pierre Boulud
CEO | Chief Executive Officer | 52 | 16-10-31 |
| Chairman | 50 | 04-04-15 | |
| Director of Finance/CFO | 47 | 18-02-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 74 | 06-09-14 | |
| Director/Board Member | 63 | 04-12-31 | |
| Chairman | 50 | 04-04-15 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.97% | 15 M€ | -3.61% | ||
| 0.26% | 1,056 M€ | +4.18% | ||
| 0.24% | 5 M€ | +4.56% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-07 | 93.8 | -1.78% | 95,457 |
| 24-06-06 | 95.5 | +0.32% | 75,849 |
| 24-06-05 | 95.2 | -0.88% | 86,720 |
| 24-06-04 | 96.05 | -0.31% | 64,910 |
| 24-06-03 | 96.35 | -0.82% | 72,272 |
Real-time Euronext Paris, June 07, 2024 at 11:35 am EDT
More quotes
bioMérieux designs, develops, produces, and sells systems used in clinical practice to diagnose infectious diseases (including HIV, tuberculosis, and respiratory infections), cancers, and cardiovascular pathologies based on a biological sample (blood, saliva, urine, etc.). Net sales break down by sector of application as follows:
- medical applications (84.4%): in industry, microbiological testing of samples from finished products, materials during the manufacturing process, or the environment, primarily in the food-processing, pharmaceutical, and cosmetics sectors;
- industrial applications (15.6%).
The group's diagnostic systems consist of three elements with related services: reagents, instruments (or platforms or analyzers), software, and services.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (32.4%), North America (44.1), Asia/Pacific (17.3%) and Latin America (6.2%).
Calendar
2024-09-03
- Q2 2024 Earnings Call
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
93.8
EUR
Average target price
113.5
EUR
Spread / Average Target
+20.98%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -6.76% | 11.98B | |
| -5.68% | 8B | |
| +8.91% | 5.85B | |
| +28.87% | 5.54B | |
| -15.84% | 3.84B | |
| +10.70% | 2.66B | |
| -60.92% | 2.62B | |
| -6.99% | 2.33B | |
| -8.85% | 1.78B | |
| -6.39% | 1.45B |
- Stock Market
- Equities
- BIM Stock
